Phenotype-Selected MSC Preparations for Consistent Therapeutic Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The heterogeneity and variability of mesenchymal stem cell (MSC) preparations lead to inconsistent therapeutic effects, making it difficult to achieve reproducible and stable therapeutic outcomes, especially in clinical settings.

Innovation Solution

Development of a method to produce uniform MSC preparations with a stable phenotype, characterized by specific antigen profiles (95% CD105+ and 95% CD166+, low CD45+), high TNFR1 expression, and resilience to cryopreservation, enabling expansion to clinical scale with consistent therapeutic potential.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional MSC preparation methods are used, then MSCs can be obtained from bone marrow, but the preparations exhibit heterogeneity and variability leading to inconsistent therapeutic effects

Engineering Contradiction:
Improvetherapeutic effect consistencyVSAvoidMSC preparation homogeneity
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent segments the MSC preparation process into distinct stages: primary culture establishment, expansion culture, and selection based on specific phenotypic markers (CD105+, CD166+, CD45-). This segmentation allows for controlled manipulation at each stage to achieve homogeneity while maintaining therapeutic reliability

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies parameter changes by selecting and expanding MSCs with specific phenotypic characteristics (CD105+, CD166+, CD45-) and controlling culture conditions (passage number, media composition, confluency). These parameter adjustments transform heterogeneous primary MSCs into homogeneous expanded preparations with consistent therapeutic effects

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If MSCs are expanded in culture to increase quantity, then therapeutic dose is achieved, but phenotypic uniformity and stability are compromised

Engineering Contradiction:
ImproveMSC cell numberVSAvoidphenotypic uniformity
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The patent implements feedback control by monitoring and selecting MSCs based on their phenotypic expression (CD105+, CD166+, CD45-) at different passage numbers. This feedback mechanism ensures that only cells maintaining the desired phenotype are expanded further, preserving uniformity while achieving therapeutic quantities

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent applies preliminary action by establishing primary cultures with specific phenotypic characteristics before expansion. By pre-selecting and characterizing MSCs at passage 0-2, the foundation for phenotypic stability during subsequent expansion is laid, preventing drift and maintaining uniformity throughout the expansion process

Inventive Principle:
Principle #10Preliminary action

3Duration of action of stationary object

If MSC preparations are subjected to cryopreservation for storage, then long-term storage is enabled, but cell viability and phenotypic stability may be reduced

Engineering Contradiction:
Improvestorage durationVSAvoidcell viability after thawing
Core Design Contradiction:
Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent applies beforehand cushioning by optimizing the MSC preparation at the passage 0-2 stage before cryopreservation. Cells are selected for robust phenotypic expression and health status, creating a cushion of quality that protects against viability loss during cryopreservation and thawing processes

Inventive Principle:
Principle #11Beforehand cushioning (Prior cushioning)

Solution Approach 2:

The patent utilizes parameter changes in the cryopreservation process itself, including controlled freezing rates, cryoprotectant concentrations, and thawing temperatures. These parameter optimizations minimize cellular stress and preserve both viability and phenotypic stability after cryopreservation

Inventive Principle:
Principle #35Parameter changes

4Adaptability or versatility

If allogeneic MSC transplantation is performed to treat patients, then therapeutic effect is achieved, but adverse effects and rejection risks increase

Engineering Contradiction:
Improvetherapeutic application rangeVSAvoidtransplant rejection and adverse effects
Core Design Contradiction:
Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by creating MSC preparations with highly specific and consistent phenotypic characteristics (CD105+, CD166+, CD45-) that are optimized for therapeutic function. This localized optimization of cell properties enhances therapeutic adaptability while reducing adverse effects through improved cell quality and reduced immunogenicity

Inventive Principle:
Principle #3Local quality

Data Source

PatentUS12410405B2Enhanced MSC preparations
Publication Date: 2025.09.09 MESOBLAST INTERNATIONAL SARL

AI summary

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.